Shukra Pharmaceuticals Share Price
08 Nov, 2026 3:32 PM (IST)
Shukra Pharmaceuticals Performance
- Today's Low
- ₹81
- Today's High
- ₹83
- 52 Week Low
- ₹26
- 52 Week High
- ₹84
- Open Price₹81
- Previous Close₹80
- Volume1,119,891
- 50 DMA₹63.80
- 100 DMA₹54.40
- 200 DMA₹46.10
Shukra Pharmaceuticals Chart
Investment Returns
- Over 1 Month + 19.18%
- Over 3 Month + 109.02%
- Over 6 Month + 131.16%
- Over 1 Year + 99.17%
Smart Investing Starts Here Start SIP with Shukra Pharmaceuticals for Steady Growth!
Shukra Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 81.5
- PEG Ratio
- 0.3
- Market Cap Cr
- 3,611
- P/B Ratio
- 35
- Average True Range
- 4.5
- EPS
- 1
- Dividend Yield
- 0
- MACD Signal
- 5.4
- RSI
- 77.53
- MFI
- 66.31
Latest Stock News Updates
Newspaper Publication of Quarterly Results
- BSE India
- 2 days 16 hours ago
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Shukra Pharmaceuticals announced Q2FY27 results</strong></span></h3> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAICBAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="pBgRuc_1k"> <li data-complete="true" data-hveid="CAAICBAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_1n"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_1p">Revenue from Operations:<!--TgQPHd|||[]--></strong> Standalone Revenue from Operations reached Rs 4,420.38 lakh in Q2FY27, demonstrating a QoQ increase of 87.92% from Rs 2,352.23 lakh in Q1FY27 and a YoY surge of 652.10% against Rs 587.74 lakh in Q2FY26. For H1FY27, Standalone Revenue from Operations stood at Rs 6,772.61 lakh compared to Rs 1,126.85 lakh in H1FY26, reflecting a YoY growth of 501.02%.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_1x"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_1z">Total Income:<!--TgQPHd|||[]--></strong> Standalone Total Income reached Rs 4,477.58 lakh in Q2FY27, marking an increase of 86.09% QoQ from Rs 2,406.20 lakh in Q1FY27 and a YoY increase of 489.93% from Rs 759.00 lakh in Q2FY26. For H1FY27, Standalone Total Income was Rs 6,883.78 lakh compared to Rs 1,409.08 lakh in H1FY26, exhibiting a YoY rise of 388.53%.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAI" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_27"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_29">Profit Before Tax (PBT):<!--TgQPHd|||[]--></strong> Standalone PBT stood at Rs 2,112.85 lakh in Q2FY27, showing a QoQ growth of 4.38% from Rs 2,024.23 lakh in Q1FY27 and a YoY surge of 10,549.45% compared to Rs 19.84 lakh in Q2FY26. For H1FY27, Standalone PBT came in at Rs 4,137.08 lakh compared to Rs 157.16 lakh in H1FY26, recording a YoY expansion of 2,532.40%.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_2h"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_2j">Profit After Tax (PAT):<!--TgQPHd|||[]--></strong> Standalone PAT recorded Rs 1,601.20 lakh in Q2FY27, increasing by 6.54% QoQ from Rs 1,502.98 lakh in Q1FY27 and climbing 573.31% YoY from Rs 237.81 lakh in Q2FY26. For H1FY27, Standalone PAT stood at Rs 3,104.18 lakh compared to Rs 340.77 lakh in H1FY26, displaying a YoY increase of 810.93%.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAICBAO" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_2r"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_2t">Earnings Per Share (EPS):<!--TgQPHd|||[]--></strong> Standalone basic and diluted EPS was Rs 0.36 in Q2FY27, an increase of 5.88% QoQ from Rs 0.34 in Q1FY27 and a 620.00% YoY increase from Rs 0.05 in Q2FY26. For H1FY27, Standalone EPS was Rs 0.71 compared to Rs 0.08 in H1FY26, growing by 787.50% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIChAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="pBgRuc_3f"> <li data-complete="true" data-hveid="CAAIChAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_3i"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_3k">Revenue from Operations:<!--TgQPHd|||[]--></strong> Consolidated Revenue from Operations was Rs 4,420.38 lakh in Q2FY27, growing 87.92% QoQ from Rs 2,352.23 lakh in Q1FY27 and jumping 652.10% YoY from Rs 587.74 lakh in Q2FY26. For H1FY27, Consolidated Revenue from Operations reached Rs 6,772.61 lakh versus Rs 1,126.85 lakh in H1FY26, expanding 501.02% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_3m"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_3o">Total Income:<!--TgQPHd|||[]--></strong> Consolidated Total Income stood at Rs 4,477.58 lakh in Q2FY27, up 86.09% QoQ from Rs 2,406.20 lakh in Q1FY27 and up 489.93% YoY from Rs 759.00 lakh in Q2FY26. For H1FY27, Consolidated Total Income recorded Rs 6,883.78 lakh compared to Rs 1,409.08 lakh in H1FY26, growing by 388.53% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_3q"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_3s">Profit Before Tax (PBT):<!--TgQPHd|||[]--></strong> Consolidated PBT was Rs 1,782.80 lakh in Q2FY27, registering a minor decrease of 1.89% QoQ against Rs 1,817.18 lakh in Q1FY27 but showing a significant YoY increase of 8,885.89% from Rs 19.84 lakh in Q2FY26. For H1FY27, Consolidated PBT stood at Rs 3,600.02 lakh compared to Rs 157.16 lakh in H1FY26, scaling up by 2,190.67% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAF" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_3u"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_3w">Profit After Tax (PAT):<!--TgQPHd|||[]--></strong> Consolidated PAT reached Rs 1,271.19 lakh in Q2FY27, dropping slightly by 1.90% QoQ from Rs 1,295.85 lakh in Q1FY27 and increasing by 434.54% YoY from Rs 237.81 lakh in Q2FY26. For H1FY27, Consolidated PAT came in at Rs 2,567.04 lakh compared to Rs 340.77 lakh in H1FY26, climbing by 653.31% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAG" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_3y"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_40">Earnings Per Share (EPS):<!--TgQPHd|||[]--></strong> Consolidated basic and diluted EPS was Rs 0.29 in Q2FY27, representing a QoQ drop of 3.33% from Rs 0.30 in Q1FY27 and a YoY expansion of 480.00% from Rs 0.05 in Q2FY26. For H1FY27, Consolidated EPS recorded Rs 0.58 compared to Rs 0.08 in H1FY26, a YoY gain of 625.00%.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><!--TgQPHd|||[]--></p> <p><strong>Business & Segment Highlights<!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]-->:</strong></p> <ul data-complete="true" data-hveid="CAAIEhAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="pBgRuc_5x"> <li data-complete="true" data-hveid="CAAIEhAC" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_60"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_62">Pharmaceutical Segment Revenue:<!--TgQPHd|||[]--></strong> Achieved Rs 3,226.93 lakh in Q2FY27, vs Rs 2,406.20 lakh in Q1FY27 and Rs 759.00 lakh in Q2FY26. H1FY27 revenue stood at Rs 5,633.13 lakh vs Rs 1,409.08 lakh in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIEhAD" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="pBgRuc_64"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="pBgRuc_66">Medtech Segment Revenue:<!--TgQPHd|||[]--></strong> Achieved Rs 1,250.65 lakh in Q2FY27 and H1FY27, with nil values in historical periods.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> </ul> <p><a class="lb" href="/get-document/post/pdf/5931371/" target="_blank">Result PDF</a></p>
- Trendlyne
- 3 days 14 hours ago
Media Release
- BSE India
- 3 days 15 hours ago
Shukra Pharmaceuticals Financials
Shukra Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹73.20
- 50 Day
- ₹63.80
- 100 Day
- ₹54.40
- 200 Day
- ₹46.10
Resistance and Support
- R3 84.90
- R2 84.00
- R1 82.70
- S1 80.50
- S2 79.60
- S3 78.40
Shukra Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-11-04 | Quarterly Results | (Revised) |
| 2026-08-22 | A.G.M. | |
| 2026-08-12 | Quarterly Results | |
| 2026-06-10 | Others | Inter-alia, to consider 1. Ratification of Approval for member's resolution passed in the EGM. 2. To approve draft of notice of postal ballot. 3. Other business matters. |
| 2026-05-07 | Audited Results & Final Dividend |
About Shukra Pharmaceuticals
Shukra Pharmaceuticals is engaged in the manufacturing, marketing, and export of pharmaceutical formulations. The Company caters to both domestic and international markets, with a growing presence in countries such as Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen. View More- NSE Symbol
- SHUKRAPHAR
- BSE Symbol
- 524632
- ISIN
- INE551C01044
Similar Stocks to Shukra Pharmaceuticals
Popular Stocks
Shukra Pharmaceuticals FAQs
Shukra Pharmaceuticals share price is ₹81 As on 09 November, 2026 | 05:20
The Market Cap of Shukra Pharmaceuticals is ₹3611 Cr As on 09 November, 2026 | 05:20
The P/E ratio of Shukra Pharmaceuticals is 81.5 As on 09 November, 2026 | 05:20
The PB ratio of Shukra Pharmaceuticals is 35 As on 09 November, 2026 | 05:20
The 52 week High & Low of Shukra Pharmaceuticals is ₹84.2/₹26.3 respectively As on 09 November, 2026 | 05:20
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.